TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07920783: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of GLR2053 Tablets Following Single and Multiple Dose Administration, and the Effect of Food in Healthy Adult Pa

Sponsor: Gan & Lee Pharmaceuticals. · Phase: PHASE1 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 124 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,614,080

Rescue Site Savings

+$3,701,784

Unlock Full NCT07920783 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07920783 Rescue Dossier →